Trials / Recruiting
RecruitingNCT06577415
A Study of RAY1225 in Participants With Impaired Liver Function
A Single Dose Pharmacokinetic Study of ray1225 in Subjects With Varying Degrees of Hepatic Impairment
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAY1225 | Administered SC |
Timeline
- Start date
- 2024-08-26
- Primary completion
- 2025-10-31
- Completion
- 2025-11-15
- First posted
- 2024-08-29
- Last updated
- 2025-03-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06577415. Inclusion in this directory is not an endorsement.